Regenesance has developed monoclonal antibody Regenemab™ for the treatment of neurodegenerative and immune mediated disorders, first target indication is PNH. The Company was founded in 2009 based on findings that inhibiting complement system factor C6 is safe and effective to block the formation of the Membrane Attack Complex and therefore preventing unwanted lysis. Since unwanted lysis by complement activation is involved in many indications, the Regenesance antibody is suitable for multiple indications like PNH, Myasthenia Gravis, Amyotrophic Lateral Sclerosis and Multiples Sclerosis.
The management team of Regenesance consists of Robert Jan Lamers (CEO), Prof. Frank Baas (CSO), and Marc van Dijk (Antibody program advisor) together offering access to a wealth of knowledge on the complement system, neurodegeneration, antibody development and production and business development. The Supervisory Board consists of Prof. dr. Jan van de Winkel, Professor David E. Housman and Tom Schwartz. This team incorporates a strong mix of entrepreneurial power, early stage drug development and scientific and operational proficiency. Supported by a skilled staff Regenesance has the required human capital to achieve its business objectives.
The main shareholders of Regenesance are: Life Science Fund Amsterdam, AMC, Stichting ALS Nederland.